SCHEMBL2769037

SCHEMBL2769037

NC(CCC1CCCCC1)C(N)c1ccc(Cl)cc1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 11/20 0.43
SLC6A3 Q01959 11/20 0.43
SLC6A2 P23975 9/20 0.43
ADRB2 P07550 1/20 0.40
METAP1 P53582 1/20 0.39
KDM1A O60341 1/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
AKT1 P31749 1/20 0.35
OPRM1 P35372 1/20 0.35
OPRL1 P41146 1/20 0.35
METAP2 P50579 1/20 0.35
CPB2 Q96IY4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8251418 1.00 SLC6A4 (0.43) SLC6A4SLC6A3SLC6A2ADRB2METAP1
SCHEMBL2771876 0.83 SLC6A4 (0.52) SLC6A4SLC6A3SLC6A2ADRB2METAP1
SCHEMBL8251822 0.83 SLC6A4 (0.52) SLC6A4SLC6A3SLC6A2ADRB2METAP1
SCHEMBL8247864 0.81 SLC6A2 (0.51) SLC6A4SLC6A3SLC6A2ADRB2METAP1
SCHEMBL2769071 0.81 SLC6A2 (0.51) SLC6A4SLC6A3SLC6A2ADRB2METAP1
SCHEMBL8249190 0.73 ADRB2 (0.45) SLC6A4SLC6A3SLC6A2ADRB2METAP1
SCHEMBL2769103 0.73 ADRB2 (0.45) SLC6A4SLC6A3SLC6A2ADRB2METAP1
SCHEMBL8719048 0.72 CNR1 (0.40) SLC6A4SLC6A3SLC6A2OPRM1OPRL1
SCHEMBL8241987 0.70 SLC6A3 (0.46) SLC6A4SLC6A3SLC6A2ADRB2AKT1
SCHEMBL2769154 0.70 SLC6A3 (0.46) SLC6A4SLC6A3SLC6A2ADRB2AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1643989-B1 CIS-IMIDAZOLINES AS MDM2 INHIBITORS HOFFMANN LA ROCHE (CH) 2010-04-28 EP disclosed
US-7132421-B2 CIS-imidazoles HOFFMANN-LA ROCHE INC. (US) 2006-11-07 US disclosed
EP-1643989-A1 CIS-IMIDAZOLINES AS MDM2 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2006-04-12 EP disclosed
WO-2005002575-A1 CIS-IMIDAZOLINES AS MDM2 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-01-13 WO disclosed
US-20040259867-A1 CIS-imidazoles FOTOUHI NADER (US) 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259867-A1 CIS-imidazoles TP53, MDM2, TP53BP1 SLC6A4 4212/4885SLC6A3 4530/4885SLC6A2 4762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.